Methods of detecting prostate carcinoma using a monoclonal antibody to a new antigenic marker in epithelial prostatic cells alone or with a monoclonal antibody to an antigen of LNCaP cells
US5763202A · kind A · utility
60Cited by
1References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 7, 1995 |
| Grant date | Jun 9, 1998 |
| Priority date | — |
| Expiry date | Jun 7, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Monoclonal antibodies to prostatic cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies show specificity for a non-soluble, membrane associated, organ specific antigenic determinant limited in its distribution to human prostate epithelial cells and normal prostatic epithelial cells. The monoclonal antibodies, specifically, 7Ell monoclonal antibodies, can be used diagnostically and therapeutically.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.